| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |